By the Peptides Lab Ireland research team · Updated July 2026 · Research-context information only
Research protocols that involve injectable delivery of research peptides are a common area in Irish preclinical research. This guide covers the reconstitution, protocol design and delivery route considerations for research groups working with injectable peptide research protocols , not human use guidance.
Injectable delivery in preclinical research
In preclinical research (cell culture, rodent and other animal models), peptides can be introduced to biological systems through several delivery routes depending on the research question:
- Subcutaneous (SC) , most common in rodent metabolic and GH-axis research protocols
- Intraperitoneal (IP) . Common for rodent studies where systemic exposure is the research readout
- Intravenous (IV) , used where research protocols require rapid systemic exposure
- Intranasal , for CNS research protocols targeting brain penetration
- Direct tissue injection , for localised tissue-repair research models
The delivery route is a research design decision that flows from the research question, not from convention.
Reconstitution for injectable research protocols
The reconstitution technique used for injectable research delivery is identical to standard peptide reconstitution see our full reconstitution guide. Summary:
- Warm both vials to room temperature
- Draw diluent with a 30G insulin syringe
- Add slowly against the vial wall, not onto the powder
- Swirl gently and don’t shake
- Allow full dissolution
Working concentration calculation: concentration (µg/ml) = (mg in vial × 1000) ÷ ml of diluent added.
Injection volume considerations in research protocols
Practical injection volume ranges in research protocols:
- Rodent SC / IP: 100–500 µl typical single-injection volume
- Larger animal SC: species-appropriate volume per institutional protocol
- Cell culture: nanoliter to microliter volumes into media
Choose reconstitution volume so that your protocol dose fits in a comfortable pipetting/injecting range (typically 100–250 µl per protocol dose) , see our BPC-157 dosing chart for a worked example.
Injectable-protocol reconstitution technique for full-length proteins
Some research peptides , with HGH 191AA, Cerebrolysin, IGF-1 LR3 , are full-length proteins rather than short peptides. Injectable research protocols with these compounds warrant extra care:
- Never shake foam is a sign of denaturation
- Roll gently between palms rather than swirl
- Reconstituted HGH should be refrigerated only , don’t freeze
- Follow batch-specific COA guidance
Full HGH detail: HGH 191AA Reconstitution and Dosing.
Injectable research supplies from Peptides Lab Ireland
- Bacteriostatic water + acetic acid water , standard reconstitution solvents
- 30G × 8 mm insulin syringes and standard research syringe for accurate low-volume aliquoting
- All research peptides in the catalogue supplied as lyophilised powder, ready for reconstitution
Compliance and regulatory framework
Injectable delivery of research peptides in Ireland operates under research chemical frameworks for in-vitro laboratory research. Not for human use under any circumstances. Institutional animal research protocols in Ireland operate under separate research-ethics and animal-welfare frameworks that Peptides Lab Ireland does not supersede.
See our HPRA guide for the regulatory context.
See also
- Peptide Reconstitution Guide
- Peptide Cold Chain and Storage
- Peptide Storage Lifetime
- BPC-157 Dosing Chart
- Retatrutide Dosage Chart
A note on regulation and research use
Every compound Peptides Lab Ireland supplies is a research chemical, not a medicine. That means it’s sold for laboratory research and educational work only, and it’s not intended for use in humans or animals. Under Irish medicines law and the HPRA framework, none of these compounds carry a medicinal product authorisation. This article gives research context. It isn’t medical, clinical, dosing or therapeutic advice.